Neurofilament light chain is a fundamental component of the neuronal cytoskeleton, particularly concentrated in the axons, which are the elongated projections responsible for transmitting nerve impulses. When axons deteriorate or rupture—a hallmark event in neurodegenerative diseases—NfL molecules escape into the bloodstream. Unlike traditional biomarkers such as amyloid-beta or tau proteins, which first indicate the presence of pathological hallmarks of AD, NfL provides a dynamic readout of ongoing neurodegeneration. Clinicians have long sought minimally invasive yet reliable markers that could track disease progression sequentially, and here, plasma NfL signifies a revolutionary advancement.

Despite the promise of NfL as a biomarker, the clinical interpretation of its plasma levels has been confounded by heterogeneous responses, particularly the underappreciated effects of biological sex on its diagnostic value. The recent synthesis underscores that, across several racially and ethnically diverse populations, men exhibit a sharper cognitive and structural brain decline than women for comparable NfL increases. This phenomenon suggests that plasma NfL isn’t a universal yardstick but rather a sex-modified biomarker, which could transform personalized medicine approaches for AD and related neurodegenerative diseases.

Such findings challenge the traditional one-size-fits-all approach in interpreting biomarker data. The clinical implication is profound: a plasma NfL concentration formerly considered moderate might in fact denote a significantly advanced neurodegenerative process in men when juxtaposed with women. This sex-dependent variance could partly explain some inconsistencies in previous research, where studies either found no difference or contradictory trends between men and women in fluid biomarkers. The interplay between NfL and sex-specific brain physiology reveals the intricate biological tapestry underlying neurodegeneration.

Technological innovations enabling ultrasensitive assays for blood-based NfL monitoring have fueled this breakthrough. Unlike PET imaging or cerebrospinal fluid collection—both costly, invasive, and logistically challenging—plasma NfL measurement involves a simple blood draw, allowing repeated assessments over time. This capability is transformative for clinical trials and patient management, enabling real-time tracking of disease progression and response to therapeutics across prodromal and preclinical stages. Remarkably, in familial AD carriers, NfL elevations can be detected years before symptom onset, offering a window into the earliest neuronal distress and an opportunity for preemptive intervention.

The mechanisms underlying the sex differences in plasma NfL’s prognostic power remain a subject of ongoing investigation. Hypotheses point towards microglial activity variations—brain immune cells that exhibit sex-specific inflammatory responses—as potential contributors to differential neuronal vulnerability. Hormonal factors, namely estrogen’s purported neuroprotective effects and testosterone’s modulating influence on brain aging, also emerge as plausible modulators. Additionally, men’s larger brain volume and higher white matter content may influence metabolite release and clearance dynamics, a concept aligned with the brain reserve theory. However, peripheral factors like blood-brain barrier permeability or renal clearance have been considered less likely to explain these observations, as they do not convincingly account for differences in neurodegeneration severity correlations.

This nuanced understanding of NfL as a dynamic and sex-influenced biomarker underscores the biological complexity of Alzheimer’s disease and challenges simplistic diagnostic paradigms. It highlights the necessity for large-scale, sex-stratified normative datasets across diverse demographics to establish individualized biomarker trajectories. Only then can clinicians accurately interpret plasma NfL levels within the context of sex, age, and disease stage. The review calls for future studies that consider these variables to optimize diagnostic precision and tailor therapeutic strategies accordingly.

Moreover, the question persists as to whether pharmacological interventions might modulate neuronal injury differently in men versus women. As our understanding deepens, sex-specific therapeutic responses may partially explain the variable efficacy observed in clinical trials and pave the way for personalized treatment algorithms. Integrating sex as a biological variable in neurodegenerative research and clinical practice emerges not as a choice but a requisite for scientific rigor and equitable health care.

At the heart of these insights lies an invitation to reimagine biomarker interpretation not as a static figure but as a fluid dialogue between biological sex, neuronal integrity, and disease progression. The blood itself remains an objective medium, but the meaning we extract from it demands careful contextualization. This paradigm shift has implications beyond Alzheimer’s, potentially reshaping biomarker utility across the spectrum of neurological disorders where neurodegeneration is a common thread.

The mini-review, authored by researchers from Fudan University and Wuhan University, showcases the power of interdisciplinary collaboration and meta-analysis to clarify complex biomedical phenomena. It redefines plasma NfL’s role within the AT(N) biomarker framework, cementing its position as the critical “N”—neurodegeneration indicator—complementing amyloid and tau pathology markers. This synthesis also illuminates gaps in knowledge and practical hurdles, including assay standardization and accessibility in resource-limited settings, which must be addressed to fully realize plasma NfL’s clinical potential globally.

As the search for effective Alzheimer’s diagnostics and treatments continues, plasma NfL offers a beacon of hope. It promises earlier detection, nuanced risk stratification, and individualized monitoring of neuroaxonal injury—provided that the scientific and medical communities embrace the imperative for sex-specific interpretation. Beyond raw numbers, this approach advocates for listening attentively to the structural whispers of the brain, tuned finely to the complexities of human biology.

Subject of Research: People

Article Title: Plasma neurofilament light chain: A biomarker for neuronal injury in Alzheimer’s disease and the imperative for sex-specific interpretation

News Publication Date: 30 June 2026

Web References:
https://doi.org/10.61373/bm026y.0051

References:
Xia Y, Yuan P, Fei G, Cheng X. Plasma neurofilament light chain: A biomarker for neuronal injury in Alzheimer’s disease and the imperative for sex-specific interpretation. Brain Medicine 2026. DOI: https://doi.org/10.61373/bm026y.0051

Image Credits:
Xiaoqin Cheng

Keywords:
Neurofilament light chain, Alzheimer’s disease, biomarker, plasma NfL, neurodegeneration, sex differences, neuroaxonal injury, diagnostic biomarker, brain reserve, cognitive decline, amyloid, tau, personalized medicine

Alzheimer’s disease (AD), a relentless neurodegenerative condition, affects millions worldwide, catalyzing memory loss and cognitive impairment that progressively worsen over time. One of the sustained challenges in Alzheimer’s research has been to uncover reliable indicators that not only capture the molecular underpinnings but also elucidate the intricate mechanisms behind structural brain alterations seen in patients. This study tackles that challenge by exploring the stage-specific mediation effect of WMHs—radiological markers believed to represent small vessel disease or demyelination—on the interplay between plasma biomarkers and cognitive functions.

The team embarked on comprehensive analyses involving plasma samples and high-resolution neuroimaging scans from participants across various disease stages, including cognitively normal subjects, individuals with mild cognitive impairment (MCI), and patients with diagnosed Alzheimer’s dementia. By leveraging advanced statistical modeling, the researchers investigated whether WMHs serve as a bridge linking peripheral biomarker fluctuations to cognitive performance deficits, paying close attention to how this interaction varies during disease progression.

At the molecular level, plasma biomarkers such as amyloid-beta peptides, tau proteins, and neurofilament light chain have garnered significant attention as minimally invasive markers indicative of neurodegeneration and Alzheimer’s-specific pathology. However, previous studies showed inconsistent correlations between these biomarkers and cognitive status, raising questions regarding the role of intermediary processes. The current investigation postulates that WMHs—often overlooked or considered mere comorbid features—could be a critical mediator influencing how plasma biomarker levels translate into neurocognitive decline.

Intriguingly, the results reveal that the mediation effect of WMHs is not uniform but distinctly dependent on disease stage. In early phases, particularly during mild cognitive impairment, plasma biomarkers exhibited a strong direct association with cognitive outcomes, with WMHs playing a moderating but not central mediating role. This suggests that in the pre-dementia period, the cerebral white matter integrity remains more resilient, allowing molecular indicators in blood to better reflect direct neuronal damage or amyloid/tau pathology.

Conversely, in later Alzheimer’s stages, the scenario shifts dramatically. Here, WMHs become a dominant mediator, insinuating that white matter disruption increasingly governs the relationship between circulating biomarkers and cognitive deficits. This stage-dependent mediation emphasizes a dynamic pathophysiological cascade, where vascular contributions and microstructural white matter damage exacerbate or even amplify the impact of molecular neuropathology on cognition.

From a technical standpoint, the study utilizes state-of-the-art neuroimaging techniques, including fluid-attenuated inversion recovery (FLAIR) MRI sequences optimized to detect WMHs with exceptional sensitivity. Coupled with high-throughput plasma biomarker assays powered by immunoassays and mass spectrometry, the data integration enabled a granular dissection of biomarker-imaging-cognition interactions. The analytical methodology incorporated advanced mediation models with rigorous adjustment for potential confounders such as age, vascular risk factors, and APOE genotype status, thereby enhancing robustness and clinical relevance.

The clinical implications of these findings are profound and manifold. Firstly, it underscores the necessity of stage-specific biomarker interpretation in Alzheimer’s diagnosis and prognosis. Diagnostic paradigms that fail to account for white matter pathology might overlook crucial contributors to cognitive decline or misattribute impairment solely to amyloid or tau levels. Secondly, the results advocate for a broadened therapeutic focus that addresses cerebrovascular health and white matter preservation alongside amyloid and tau-targeting strategies, potentially offering synergistic benefits.

Moreover, this research paves the way for personalized medicine approaches in Alzheimer’s care. By delineating distinct mechanistic pathways at different disease junctures, clinicians might tailor monitoring protocols and interventions—implementing vascular protective measures more aggressively in advanced stages where WMHs mediation predominates, while focusing on direct modulation of molecular pathology in early disease.

An additional dimension worth noting is the potential utility of WMHs as surrogate endpoint markers in clinical trials. Their role as mediators highlights their informational value in assessing treatment efficacy and disease progression beyond traditional cognitive scales and fluid biomarkers alone. Incorporating WMH quantification could refine trial designs, improving sensitivity to detect meaningful changes in brain integrity and correlating better with functional outcomes.

This paradigm-shifting study also raises compelling questions about the pathophysiological synergy between neurodegeneration and small vessel disease in Alzheimer’s. It prompts further investigation into mechanisms driving WMHs formation—be it chronic hypoperfusion, blood-brain barrier breakdown, or inflammatory processes—and how these factors interact with amyloidopathy and tauopathy. Such insights could unlock new biomolecular targets aimed at halting or reversing white matter damage.

Ultimately, the work of Chen and colleagues represents a critical leap toward an integrated biomarker framework that captures the complex heterogeneity of Alzheimer’s disease at molecular, structural, and cognitive levels. Its nuanced acknowledgment of disease-stage specificity highlights the importance of multidimensional analysis and challenges reductionist views that isolate singular pathological features.

As the field moves forward, adoption of combined plasma biomarker and neuroimaging assessment protocols promises to enhance early detection, track disease evolution with greater fidelity, and guide personalized intervention. The intricate dance between peripheral biomarkers, white matter integrity, and cognition revealed here not only enriches scientific understanding but also fuels hope for more effective strategies against one of the most challenging disorders confronting aging populations globally.

In conclusion, this seminal investigation of stage-dependent mediation of WMHs between plasma biomarkers and cognitive function unearths vital insights into the intertwined nature of vascular and neurodegenerative pathology in Alzheimer’s disease. The evidence foregrounds a complex, evolving interplay that demands comprehensive, stage-attuned perspectives for both research and clinical application. With further validation and expansion, these findings have the potential to transform Alzheimer’s diagnosis, treatment, and ultimately, patient outcomes worldwide.

Subject of Research: Alzheimer’s disease, plasma biomarkers, white matter hyperintensities, cognitive function, neuroimaging, disease stage mediation

Article Title: Stage-Dependent mediation of white matter hyperintensities between plasma biomarkers and cognitive function in Alzheimer’s disease

Article References:
Chen, H.J., Guo, Y., Huang, W. et al. Stage-Dependent mediation of white matter hyperintensities between plasma biomarkers and cognitive function in Alzheimer’s disease. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03927-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03927-5